Improving Prostate Cancer Biopsy Targeting With MRI and Real-Time Metabolic Feedback
Builds a system to guide where biopsy samples are taken in prostate cancer.
Plain-language title generated from the registry record
Registry title: Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
Key facts
- Where
- Shanghai, ChinaSee the 4 sites
Where in China
- Minhang Hospital, Fudan UniversityShanghai, ChinaTaking people
- Shanghai Geriatric Medical CenterShanghai, ChinaTaking people
- Xuhui Hospital, Fudan UniversityShanghai, ChinaTaking people
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Zhongshan Hospital
- Trial code
- NCT07856017
- Record updated
- 2 October 2026
- Original description
Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.Read full original descriptionShow less
An MRI-Based Diagnostic Model for Prostate Cancer Localization: An Exploratory Study Integrating Radiomics and the Metabolic Microenvironment
Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.
Inclusion: Age ≥55 years; Indication for prostate biopsy; Availability of total prostate-specific antigen (tPSA), free PSA (fPSA) levels, and multiparametric MRI (mpMRI) results within 1 month prior to biopsy.
Exclusion: Concomitant malignant tumors potentially affecting imaging findings (e.g., rectal, bladder, or testicular cancer); Pathological diagnosis of malignancies other than prostatic acinar adenocarcinoma; Cachexia or organ function decompensation.